• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by CalciMedica Inc.

    6/27/25 4:03:04 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALC alert in real time by email
    S-8 POS 1 d917898ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on June 27, 2025

    Registration No. 333-288287

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    CalciMedica, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   45-2120079

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    505 Coast Boulevard South, Suite 307

    La Jolla, California

      92037
    (Address of Principal Executive Offices)   (Zip Code)

    2023 Equity Incentive Plan

    2023 Employee Stock Purchase Plan

    (Full titles of the plans)

    A. Rachel Leheny, Ph.D.

    Chief Executive Officer

    505 Coast Boulevard South, Suite 307

    La Jolla, California 92037

    (858) 952-5500

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Thomas A. Coll

    Carlos Ramirez

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

     

    John M. Dunn

    General Counsel

    505 Coast Boulevard South, Suite 307

    La Jolla, California 92037

    (858) 550-6000   (858) 952-5500

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (Registration No. 333-288287) previously filed with the SEC on June 24, 2025 (the “Registration Statement”) is being filed solely for the purpose of filing Exhibit 23.3 thereto, which was inadvertently omitted when the Registration Statement was filed. All other portions of the Registration Statement, as previously filed, remain unchanged.

    PART I

    ITEM 8. EXHIBITS.

     

    Exhibit
    Number
      

    Description

      4.1    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
      4.2    Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
      4.3    Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020).
      5.1**    Opinion of Cooley LLP.
     23.1**    Consent of Baker Tilly, US, LLP, Independent Registered Public Accounting Firm.
     23.2**    Consent of Cooley LLP. Reference is made to Exhibit 5.1.
     23.3*    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
     24.1**    Power of Attorney (included on the signature page of the Registrant’s Registration Statement on Form S-8 (Registration No. 333-288287) filed with the SEC on June 24, 2025).
     99.1**    CalciMedica, Inc. 2023 Equity Incentive Plan.
     99.2    Form of Option Grant Notice and Option Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
     99.3    Forms of Restricted Stock Unit Grant Notice and Unit Award Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
     99.4    CalciMedica, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.9 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on May 12, 2023).

     

    *

    Filed herewith.

    **

    Previously filed.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of La Jolla, State of California, on June 27, 2025.

     

    CALCIMEDICA, INC.
    By:  

    /s/ A. Rachel Leheny, Ph.D.

      A. Rachel Leheny, Ph.D.
      Chief Executive Officer

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 1 to the Registration Statement on Form S-8, has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /S/ A. RACHEL LEHENY, PH.D.

    A. Rachel Leheny, Ph.D.

       Chief Executive Officer and Director
    (Principal Executive Officer)
      June 27, 2025

    /S/ STEPHEN BARDIN

    Stephen Bardin

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      June 27, 2025

    *

    Robert N. Wilson

       Chairman   June 27, 2025

    *

    Alan Glicklich

       Director   June 27, 2025

    *

    Frederic Guerard, Pharm.D.

       Director   June 27, 2025

    *

    Fred Middleton

       Director   June 27, 2025

    *

    Eric W. Roberts

       Director   June 27, 2025

    *

    Allan Shaw

       Director   June 27, 2025

     

    *By:   /s/ A. RACHEL LEHENY, PH.D.
      A. Rachel Leheny, Ph.D.
      Attorney-in-Fact
    Get the next $CALC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CALC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CALC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF BUSINESS OFFICER Roberts Eric W bought $15,600 worth of shares (5,000 units at $3.12) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/15/25 12:31:52 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,378 worth of shares (2,343 units at $3.15) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/11/25 12:00:07 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $28,532 worth of shares (10,000 units at $2.85) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/2/25 1:05:22 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

    LA JOLLA, Calif., Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET. A live webcast of the presentation can be accessed in the "IR Events and Pr

    9/2/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026  Productive initial meeting with the FDA on Auxora in acute pancreatitis (AP); conversations continue, with alignment on a pivotal trial anticipated around the end of 2025 Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., Aug. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported fin

    8/12/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

    LA JOLLA, Calif., July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025, at 2:00 p.m. ET. A live webcast of the presentation can be accessed in the "IR

    7/8/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    SEC Filings

    View All

    $CALC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 10-Q filed by CalciMedica Inc.

    10-Q - CalciMedica, Inc. (0001534133) (Filer)

    8/12/25 4:15:33 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CalciMedica, Inc. (0001534133) (Filer)

    8/12/25 7:30:28 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CalciMedica Inc.

    SCHEDULE 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    8/5/25 7:32:14 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $15,600 worth of shares (5,000 units at $3.12) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/15/25 12:31:52 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,378 worth of shares (2,343 units at $3.15) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/11/25 12:00:07 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $28,532 worth of shares (10,000 units at $2.85) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/2/25 1:05:22 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Leadership Updates

    Live Leadership Updates

    View All

    CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    5/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    3/27/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

    LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D. to the Company's Board of Directors effective on January 15, 2025. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics.

    1/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Financials

    Live finance-specific insights

    View All

    CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

    Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m. PT LA JOL

    10/30/24 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

    Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutt

    10/28/24 4:05:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

    Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.

    8/12/24 4:10:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CalciMedica Inc.

    SC 13D - CalciMedica, Inc. (0001534133) (Subject)

    11/26/24 6:03:55 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

    SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    11/14/24 3:32:39 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

    SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    11/14/24 1:05:20 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care